207 related articles for article (PubMed ID: 28743221)
1. Components of metabolic syndrome and prognosis of renal cell cancer.
Eskelinen TJ; Kotsar A; Tammela TLJ; Murtola TJ
Scand J Urol; 2017 Dec; 51(6):435-441. PubMed ID: 28743221
[TBL] [Abstract][Full Text] [Related]
2. Number of Metabolic Syndrome Components Is the Central Predictor of the Impact of Metabolic Syndrome on Outcome of Percutaneous Nephrolithotomy in Staghorn Nephrolithiasis.
Xu P; Wang J
J Endourol; 2019 Nov; 33(11):946-953. PubMed ID: 31333070
[No Abstract] [Full Text] [Related]
3. The associations of metabolic syndrome with incident hypertension, type 2 diabetes mellitus and chronic kidney disease: a cohort study.
Ding C; Yang Z; Wang S; Sun F; Zhan S
Endocrine; 2018 May; 60(2):282-291. PubMed ID: 29492904
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
[TBL] [Abstract][Full Text] [Related]
5. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer.
Kocher NJ; Rjepaj C; Robyak H; Lehman E; Raman JD
World J Urol; 2017 Jan; 35(1):67-72. PubMed ID: 27189620
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome prevalence in renal cell cancer patients.
Bulut S; Aktas BK; Erkmen AE; Ozden C; Gokkaya CS; Baykam MM; Memis A
Asian Pac J Cancer Prev; 2014; 15(18):7925-8. PubMed ID: 25292088
[TBL] [Abstract][Full Text] [Related]
7. Association between metabolic syndrome and kidney cancer risk: a prospective cohort study.
Wang L; Du H; Sheng C; Dai H; Chen K
Lipids Health Dis; 2024 May; 23(1):142. PubMed ID: 38760801
[TBL] [Abstract][Full Text] [Related]
8. The metabolic syndrome and its components as prognostic factors in metastatic colorectal cancer.
Reed M; Patrick C; Croft B; Walde N; Voutsadakis IA
Indian J Gastroenterol; 2019 Feb; 38(1):15-22. PubMed ID: 30701442
[TBL] [Abstract][Full Text] [Related]
9. The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma.
Rampersaud EN; Klatte T; Bass G; Patard JJ; Bensaleh K; Böhm M; Allhoff EP; Cindolo L; De La Taille A; Mejean A; Soulie M; Bellec L; Christophe Bernhard J; Pfister C; Colombel M; Belldegrun AS; Pantuck AJ; George D
Urol Oncol; 2014 Jan; 32(1):30.e9-13. PubMed ID: 23422777
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study.
Antonelli A; Arrighi N; Corti S; Zanotelli T; Cozzoli A; Cosciani Cunico S; Simeone C
Urol Oncol; 2013 Oct; 31(7):1310-5. PubMed ID: 22281433
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the association of current cigarette smoking and outcome for patients with clear cell renal cell carcinoma.
Parker A; Lohse C; Cheville J; Leibovich B; Igel T; Blute M
Int J Urol; 2008 Apr; 15(4):304-8. PubMed ID: 18380816
[TBL] [Abstract][Full Text] [Related]
13. Components of metabolic syndrome and their combinations as predictors of cardiovascular disease in Japanese patients with type 2 diabetes. Implications for improved definition. Analysis from Japan Diabetes Complications Study (JDCS).
Sone H; Tanaka S; Iimuro S; Oida K; Yamasaki Y; Oikawa S; Ishibashi S; Katayama S; Ito H; Ohashi Y; Akanuma Y; Yamada N
J Atheroscler Thromb; 2009 Aug; 16(4):380-7. PubMed ID: 19672033
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study.
Nam GE; Kim SM; Han K; Kim NH; Chung HS; Kim JW; Han B; Cho SJ; Yu JH; Park YG; Choi KM
PLoS Med; 2018 Aug; 15(8):e1002640. PubMed ID: 30130376
[TBL] [Abstract][Full Text] [Related]
15. A novel prognostic model for patients with sarcomatoid renal cell carcinoma.
Zhang BY; Thompson RH; Lohse CM; Leibovich BC; Boorjian SA; Cheville JC; Costello BA
BJU Int; 2015 Mar; 115(3):405-11. PubMed ID: 24730416
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma.
Parker WP; Lohse CM; Zaid HB; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Urol Oncol; 2017 Jan; 35(1):36.e1-36.e6. PubMed ID: 27687543
[TBL] [Abstract][Full Text] [Related]
17. Metastatic potential of a renal mass according to original tumour size at presentation.
Umbreit EC; Shimko MS; Childs MA; Lohse CM; Cheville JC; Leibovich BC; Blute ML; Thompson RH
BJU Int; 2012 Jan; 109(2):190-4; discussion 194. PubMed ID: 21557795
[TBL] [Abstract][Full Text] [Related]
18. Kidney size and cancer-specific survival for patients undergoing nephrectomy for pT1 clear cell renal cell carcinoma.
Jorns JJ; Thiel DD; Lohse C; Williams A; Arnold M; Cheville J; Leibovich B; Parker AS
Urology; 2012 Jul; 80(1):147-50. PubMed ID: 22748870
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma.
Kriegmair MC; Mandel P; Porubsky S; Dürr J; Huck N; Nuhn P; Pfalzgraf D; Michel MS; Wagener N
Horm Cancer; 2017 Apr; 8(2):127-134. PubMed ID: 28247362
[TBL] [Abstract][Full Text] [Related]
20. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
